NKTR: Summary for Nektar Therapeutics - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 10:57am EST - Canadian Markets close in 5 hours and 3 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Nektar Therapeutics (NKTR)

At 10:41 EST: 8.83 USD

0.13 (1.49%)

MORE ON NKTR

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Nektar Therapeutics (NasdaqNM:NKTR) Delayed quote data

Last Trade:	8.83 USD
Trade Time:	10:41AM EST
Change:	0.13 (1.49%)
Prev Close:	8.70
Open:	8.69
Bid:	8.85 x 300
Ask:	8.87 x 200
1y Target Est:	10.55

Day's Range:	8.66 - 8.97
52wk Range:	3.90 - 10.64
Volume:	80,728
Avg Vol (3m):	759,258
Market Cap:	822.93M
P/E (ttm):	N/A
EPS (ttm):	-1.21
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add NKTR to Portfolio

Download Data

HEADLINES

•	Abbott: Brave or Stupid?
	at Motley Fool (Fri, Nov 13)

•	AstraZeneca Beats, Raises
	Zacks.com (Fri, Nov 13)

•	NEKTAR THERAPEUTICS Financials
	EDGAR Online Financials (Tue, Nov 10)

•	New Star Analyst Rankings for Nektar Therapeutics
	StarMine (Thu, Nov 5)

•	NEKTAR THERAPEUTICS Files SEC form 10-Q, Quarterly Report
	EDGAR Online (Thu, Nov 5)

•	Nektar Therapeutics Financial Results Call scheduled for 5:00 pm ET today
	CCBN (Wed, Nov 4)

•	NEKTAR THERAPEUTICS Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
	EDGAR Online (Wed, Nov 4)

•	Nektar Therapeutics Reports Third Quarter 2009 Financial Results
	PRNewswire (Wed, Nov 4)

•	Q3 2009 Nektar Therapeutics Earnings Release - Time Not Supplied
	CCBN (Wed, Nov 4)

•	Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
	PRNewswire (Thu, Oct 29)

•	Nektar Completes Enrollment Ahead of Schedule in Phase 2 Clinical Trial Evaluating NKTR-102 in Patients with Platinum-Resistant Ovarian Cancer
	PRNewswire (Wed, Oct 28)

More Headlines for NKTR...

ANALYST

EPS Est (next year) (Dec-07) :	N/A
EPS Est (in 2 years) (Dec-08) :	N/A
Avg Rec (current)*:	2.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies.

Full Company Profile

Add to Portfolio

Email to a Friend

•